APA

Bourlière M., Gordon S. C., Schiff E. R., Tran T. T., Ravendhran N., Landis C. S., Hyland R. H., Stamm L. M., Zhang J., Dvory-Sobol H., Subramanian G. M., Brainard D. M., McHutchison J. G., Serfaty L., Thompson A. J., Sepe T. E., Curry M. P., Reddy K. R. & Manns M. P. (20190307). Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1. : The lancet. Gastroenterology & hepatology.

Chicago

Bourlière Marc, Gordon Stuart C, Schiff Eugene R, Tran Tram T, Ravendhran Natarajan, Landis Charles S, Hyland Robert H, Stamm Luisa M, Zhang Jie, Dvory-Sobol Hadas, Subramanian G Mani, Brainard Diana M, McHutchison John G, Serfaty Lawrence, Thompson Alex J, Sepe Thomas E, Curry Michael P, Reddy K Rajender and Manns Michael P. 20190307. Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1. : The lancet. Gastroenterology & hepatology.

Harvard

Bourlière M., Gordon S. C., Schiff E. R., Tran T. T., Ravendhran N., Landis C. S., Hyland R. H., Stamm L. M., Zhang J., Dvory-Sobol H., Subramanian G. M., Brainard D. M., McHutchison J. G., Serfaty L., Thompson A. J., Sepe T. E., Curry M. P., Reddy K. R. and Manns M. P. (20190307). Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1. : The lancet. Gastroenterology & hepatology.

MLA

Bourlière Marc, Gordon Stuart C, Schiff Eugene R, Tran Tram T, Ravendhran Natarajan, Landis Charles S, Hyland Robert H, Stamm Luisa M, Zhang Jie, Dvory-Sobol Hadas, Subramanian G Mani, Brainard Diana M, McHutchison John G, Serfaty Lawrence, Thompson Alex J, Sepe Thomas E, Curry Michael P, Reddy K Rajender and Manns Michael P. Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1. : The lancet. Gastroenterology & hepatology. 20190307.